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Clinically, the Berlin ARDS definition describes acute respiratory distress syndrome (ARDS) as acute 
hypoxemic respiratory failure, that is not fully explained by cardiac failure or fluid overload, that 
develops within seven days of clinical recognition of a known risk factor, with bilateral radiographic 
opacities that are not fully explained by effusions, lobar/lung collapse, or nodules. Three risk strata 
were defined, based on the severity of hypoxemia represented by the ratio of partial pressure of 
oxygen in arterial blood to inspired oxygen concentration (PaO2/FiO2 ratio), assessed at a minimum 
positive end-expiratory pressure (PEEP) of 5 centimetres of water [1]. Hospital mortality worsens with 
severity of hypoxaemia and thus grade of ARDS (from 35% in mild ARDS to 46% in severe ARDS) [1, 
2].  
 
The ARDS consensus definitions to-date have mainly relied on feasible clinical criteria, which helps to 
group patients together for inclusion in clinical trials and for clinical management [1, 3]. This generates 
clinical and biological differences in observable patient characteristics. These differences are 
associated with inter-individual variation in the risk of illness, risk of outcomes from the illness, 
response to treatments administered for the illness and combinations thereof (referred to as 
heterogeneity)[4, 5]. For example, pneumonia is a common risk factor for ARDS [2, 3, 6]. However, 
not every patient admitted with pneumonia develops ARDS. One possible explanation is that there 
are differences in host responses between patients, as observed by variation in biomarker profiles for 
the same risk factor [7] . Amongst patients with pneumonia who develop ARDS, the severity and 
outcome vary between cohorts. This ARDS heterogeneity has contributed towards many statistically 
negative randomised controlled trials (RCT) [6].  
 
Thus, identifying subgroups of ARDS patients (referred to as ARDS sub-phenotypes in the literature) 
who either have a higher risk of mortality (prognostic enrichment), or differences in treatment 
responses and/or similar biological mechanisms that are modifiable (predictive enrichment) could 
enable stratified and/or precision medicine [5].  To-date, two ARDS sub-phenotypes have been 
reported from reanalyses of five RCTs [8-12], and in one observational cohort study [13], where the 
sub-phenotype membership was determined by similarities in the observable clinical and biological 
features. Although, all six studies report two ARDS sub-phenotypes, they differ in the biomarkers, 
clinical characteristics, and analytic approaches used. All RCT reanalyses used biomarker and clinical 
characteristics with latent class analyses to determine ARDS sub-phenotypes [8-12]. All RCTs report 
a hyperinflammatory sub-phenotype characterised by higher plasma concentrations of inflammatory 
biomarkers, greater vasopressor use, lower serum bicarbonate concentrations, and a higher 
prevalence of sepsis, when compared to the more common hypoinflammatory (Phenotype-1) sub-
phenotype [8-12]. This hyperinflammatory sub-phenotype has higher mortality (prognostic 
enrichment) and different treatment responses to PEEP, simvastatin, and fluid management 
(predictive enrichment) [8-11], which may reflect true biological effect modification. Importantly, these 
two phenotypes could be distinguished with a three-variable model of serum interleukin-8 (IL-8) or IL-
6, bicarbonate, and soluble tumor necrosis factor receptor-1 (sTNFR-1), in patients enrolled within the 
ARDS Network RCTs of lower versus higher tidal volume ventilation (ARMA), higher versus lower 
positive end-expiratory pressure (ALVEOLI), and the Fluid and Catheter Treatment Trial (FACTT) [8, 
9]. In contrast, the observational cohort study used only biomarker data with clustering analysis to 
determine ARDS sub-phenotypes [13]. The reactive sub-phenotype reported in the observational 
study had higher mortality when compared to the uninflamed sub-phenotype [13] and could be 
distinguished with a four-variable biomarker panel consisting of IL-6, interferon gamma, angiopoietin 
1, angiopoietin 2, and plasminogen activator inhibitor-1 [Figure-1]. While up to a third of patients with 
ARDS progressed to more severe risk strata over the first 7 days [1, 2], these ARDS sub-phenotypes 
remained stable over first three days of enrolment into ARMA and ALVEOLI trials [11]. 
 
Prior to any attempts at incorporating management directed to ARDS sub-phenotypes into routine 
clinical practice, a number of important questions need to be answered. The prevalence of reactive 
sub-phenotypes was twice as common in the observational cohort study compared to the 
hyperinflammatory sub-phenotypes in RCTs. It is not clear if this is due to selection bias inherent to 
randomized trials or to differences in biology. We need to ascertain whether the reactive and 
hyperinflammatory sub-phenotypes are phenotypically and/or biologically similar. As infection is the 
most common risk factor for ARDS, similarities of ARDS sub-phenotypes to sepsis sub-phenotypes 
should be explored. Prospective validation studies with a standardised approach to ARDS sub-
phenotyping are needed and could be an international inception cohort study similar to the LUNG-
SAFE study [2]. As radiology and need for minimum PEEP are challenging elements of the Berlin 
Definition, acute hypoxemic respiratory failure (i.e., PaO2/FiO2 ≤ 300 regardless of PEEP level) could 
be the inception cohort, which then could be used to identify ARDS patients within the AHRF cohort. 
The study aims are then to determine similarities and differences between acute hypoxemic 
respiratory failure and ARDS, alongside validating ARDS sub-phenotypes. Studying biological signals 
in this context requires a comprehensive set of data of different biological dimensions (e.g., gene 
expression on leukocytes [leukocyte transcriptome], and altered patterns of protein components in 
blood [proteome], in addition to detailed clinical phenotyping). This research should resemble a 
system biology research cycle and could begin with the hypothesis that there are at least two 
biologically distinct ARDS sub-phenotypes and that these ARDS sub-phenotypes have differences in 
risk of death and treatment response. There is a clinical need to identify biomarkers that are 
associated with treatment response, independent of group membership.  Therefore, consensus on 
biological sampling time-points, biological dimension measured, and a standard minimum set of 
consensus biomarkers is required. The biological sampling should aim to reflect the insults to the 
alveolar capillary membrane (ACM) (exudative phase), deposition of provisional matrix with 
proliferation of airway progenitor cells (proliferative phase), or interstitial and intra alveolar fibrosis 
(fibrotic phase) of ARDS. This minimum set of markers could then be used to delineate discriminant 
markers of ARDS sub-phenotypes that provide prognostic enrichment with either a greater probability 
of therapeutically valid similarities or a greater likelihood of treatment response.
Legend 
Figure-1: ARDS Phenotyping 
  
 
Broadly, the term phenotype refers to observable characteristics of an organism. The observable 
differences in clinical and biological characteristics could be used to group ARDS patients, referred to 
as ARDS sub-phenotypes. ARDS sub-phenotypes have been reported from five randomised 
controlled trials and one observational cohort study. There are differences in the variables and the 
method used to define ARDS sub-phenotypes, which are summarised in the figure. 
1The Respiratory system variables included minute ventilation, mean airway pressure, plateau 
pressure, respiratory rate, tidal volume, positive end-expiratory pressure; partial pressure PaO2 of 
carbon dioxide (PaCO2) and ratio of partial pressure of oxygen in arterial blood to inspired oxygen 
concentration (PaO2/FiO2 ratio). The Cardiovascular system variables include highest heart rate, 
lowest systolic blood pressure and vasopressor use. The renal variables included creatinine, urea and 
urine output. ANG1/2, angiopoietin 1 and 2; BMI, body mass index; CRP – C reactive protein; GM-
CSF, granulocyte-monocyte colony stimulating factor; HCO3, bicarbonate; ICAM-1, intracellular 
adhesion molecule-1; IFN-γ, interferon gamma; IL, interleukins 6, 8, 10, 13; IL-1β, interleukin-1 beta; 
LDH – lactate dehydrogenase; MMP-8, matrix metalloproteinase-8; P/F, PaO2/FiO2 ratio; PAI-1, 
plasminogen activator inhibitor-1; PCT – procalcitonin; sRAGE, soluble receptor for advanced 
glycation end products; RCT, randomised controlled trial; SP-D, surfactant protein-D; sTNFR-1, 
soluble tumour necrosis factor receptor-1; TIMP-1, tissue inhibitor of metalloproteinase-1; TNF-α, 
tumor necrosis factor-alpha; TNFR – tumor necrosis factor receptor; tPA, tissue plasminogen 
activator; vWF, von-Williebrand’s factor; VeGF – vascular endothelial growth factor; WBC, white blood 
cell count.  
Biomarkers
• Lung epithelial: SP-D; sRAGE
• Endothelial: ANG2; ICAM-1; vWF; 
• Coagulation: PAI-1; Protein-C
• Inflammation: IL-6; IL-8; sTNFR; CRP; 
WCC
ARDS Sub-Phenotypes
All RCT reanalyses 
uses clinical variables and biomarkers
Observational cohort analysis
uses only biomarkers
Clinical variables
• Demographics: Age; gender; ethnicity; 
BMI
• ARDS aetiology: trauma; sepsis; 
aspiration; pneumonia or other 
• Organ dysfunction: Respiratory1; CVS1; 
Bilirubin; Platelets; Renal1
• Other: Temperature; Sodium; Glucose; 
Albumin; bicarbonate
Biomarkers
• Lung epithelial: None
• Endothelial: E-selectin; P-selectin; 
ANG1/2 
• Coagulation: antithrombin; D-Dimer; 
tPA; PAI-1
• Inflammation: fractalkine; GM-CSF; 
ICAM-1; IFN-γ; IL-1β; IL-6; IL-8; IL-10; IL-
13; TNF-α; MMP-8; TIMP-1 
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